Cancer Stem Cells of Hepatocellular Carcinoma

  • Gangming Zou
  • Jinjun Li
  • Jianren Gu


Hepatocellular carcinoma (HCC) is one of the most aggressive cancers with a poor prognosis. HCC is suggested to originate from the malignant transformation of liver-resident stem/progenitor cells. HCC cancer stem cells (CSCs) have been characterized recently and the phenotype of those cells has been defined as CD133+CD44+ cancer cells. Also, HCC CSCs with other immunophenotypic characters EpCAM, OV6 and others have been reported. Those malignant stem cells are related to high self-renewal, potent tumorigenic capability and drug resistance. These advances will highlight the new strategy in HCC treatment. This chapter describes the current status and progress of cancer stem cell research in HCC. The challenges in cancer stem cell hypothesis and relevant models in cancer initiation and progression will be discussed.


Cancer Stem Cell Side Population ABCG2 Expression Hepatic Stem Cell Cancer Stem Cell Hypothesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Yin S, Li J, Hu C, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer, 2007, 120: 1444–1450.PubMedCrossRefGoogle Scholar
  2. [2]
    Suetsugu A, Nagaki M, Aoki H, et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun, 2006, 351: 820–824.PubMedCrossRefGoogle Scholar
  3. [3]
    Chiba T, Kita K, Zheng Y W, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology, 2006, 44: 240–251.PubMedCrossRefGoogle Scholar
  4. [4]
    Chiba T, Zheng Y W, Kita K, et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology, 2007, 133: 937–950.PubMedCrossRefGoogle Scholar
  5. [5]
    Ma S, Chan K W, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology, 2007, 132: 2542–2556.PubMedCrossRefGoogle Scholar
  6. [6]
    Zhu Z, Hao X, Yan M, et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer, 2010, 126: 2067–2078.PubMedCrossRefGoogle Scholar
  7. [7]
    Kondo M, Wagers A J, Manz M G, et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol, 2003, 21: 759–806.PubMedCrossRefGoogle Scholar
  8. [8]
    McCulloch E A, Till J E. Perspectives on the properties of stem cells. Nat Med, 2005, 11: 1026–1028.PubMedCrossRefGoogle Scholar
  9. [9]
    Becker A J, Mc C E, Till J E. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature, 1963, 197: 452–454.PubMedCrossRefGoogle Scholar
  10. [10]
    Siminovitch L, McCulloch E A, Till J E. The distribution of colony-forming cells among spleen colonies. J Cell Physiol, 1963, 62: 327–336.PubMedCrossRefGoogle Scholar
  11. [11]
    Schmelzer E, Zhang L, Bruce A, et al. Human hepatic stem cells from fetal and postnatal donors. J Exp Med, 2007, 204: 1973–1987.PubMedCrossRefGoogle Scholar
  12. [12]
    Bonnet D, Dick J E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med, 1997, 3: 730–737.PubMedCrossRefGoogle Scholar
  13. [13]
    Ricci-Vitiani L, Lombardi D G, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature, 2007, 445: 111–115.PubMedCrossRefGoogle Scholar
  14. [14]
    Al-Hajj M, Wicha M S, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA, 2003, 100: 3983–3988.PubMedCrossRefGoogle Scholar
  15. [15]
    Curley M D, Therrien V A, Cummings C L, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells, 2009, 27: 2875–2883.PubMedGoogle Scholar
  16. [16]
    Li C, Heidt D G, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res, 2007, 67: 1030–1037.PubMedCrossRefGoogle Scholar
  17. [17]
    Zou G M. Cancer stem cells in leukemia, recent advances. J Cell Physiol, 2007, 213: 440–444.PubMedCrossRefGoogle Scholar
  18. [18]
    Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer, 2008, 8: 545–554.PubMedCrossRefGoogle Scholar
  19. [19]
    Yamashita T, Budhu A, Forgues M, et al. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res, 2007, 67: 10831–10839.PubMedCrossRefGoogle Scholar
  20. [20]
    Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology, 2009, 136: 1012–1024.PubMedCrossRefGoogle Scholar
  21. [21]
    Yang Z F, Ho D W, Ng M N, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell, 2008, 13: 153–166.PubMedCrossRefGoogle Scholar
  22. [22]
    Yang Z F, Ngai P, Ho D W, et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology, 2008, 47: 919–928.PubMedCrossRefGoogle Scholar
  23. [23]
    Yang W, Yan H X, Chen L, et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res, 2008, 68: 4287–4295.PubMedCrossRefGoogle Scholar
  24. [24]
    Miraglia S, Godfrey W, Yin A H, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood, 1997, 90: 5013–5021.PubMedGoogle Scholar
  25. [25]
    Yin A H, Miraglia S, Zanjani E D, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood, 1997, 90: 5002–5012.PubMedGoogle Scholar
  26. [26]
    Weigmann A, Corbeil D, Hellwig A, et al. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci USA, 1997, 94: 12425–12430.PubMedCrossRefGoogle Scholar
  27. [27]
    Horn P A, Tesch H, Staib P, et al. Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells. Blood, 1999, 93: 1435–1437.PubMedGoogle Scholar
  28. [28]
    Litvinov S V, Velders M P, Bakker H A, et al. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol, 1994, 125: 437–446.PubMedCrossRefGoogle Scholar
  29. [29]
    Baeuerle P A, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer, 2007, 96: 417–423.PubMedCrossRefGoogle Scholar
  30. [30]
    Trzpis M, McLaughlin P M, de Leij L M, et al. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol, 2007, 171: 386–395.PubMedCrossRefGoogle Scholar
  31. [31]
    de Boer C J, van Krieken J H, Janssen-van Rhijn C M, et al. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol, 1999, 188: 201–206.PubMedCrossRefGoogle Scholar
  32. [32]
    Okegawa T, Pong R C, Li Y, et al. The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta Biochim Pol, 2004, 51: 445–457.PubMedGoogle Scholar
  33. [33]
    Schmelzer E, Wauthier E, Reid L M. The phenotypes of pluripotent human hepatic progenitors. Stem Cells, 2006, 24: 1852–1858.PubMedCrossRefGoogle Scholar
  34. [34]
    Ji J, Yamashita T, Budhu A, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology, 2009, 50: 472–480.PubMedCrossRefGoogle Scholar
  35. [35]
    Ades E W, Zwerner R K, Acton R T, et al. Isolation and partial characterization of the human homologue of Thy1. J Exp Med, 1980, 151: 400–406.PubMedCrossRefGoogle Scholar
  36. [36]
    Dezso K, Jelnes P, Laszlo V, et al. Thy1 is expressed in hepatic myofibroblasts and not oval cells in stem cell-mediated liver regeneration. Am J Pathol, 2007, 171: 1529–1537.PubMedCrossRefGoogle Scholar
  37. [37]
    Kon J, Ichinohe N, Ooe H, et al. Thy1-positive cells have bipotential ability to differentiate into hepatocytes and biliary epithelial cells in galactosamine-induced rat liver regeneration. Am J Pathol, 2009, 175: 2362–2371.PubMedCrossRefGoogle Scholar
  38. [38]
    Crosby H A, Hubscher S G, Joplin R E, et al. Immunolocalization of OV-6, a putative progenitor cell marker in human fetal and diseased pediatric liver. Hepatology, 1998, 28: 980–985.PubMedCrossRefGoogle Scholar
  39. [39]
    Goodell M A, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med, 1996, 183: 1797–1806.PubMedCrossRefGoogle Scholar
  40. [40]
    Chiba T, Miyagi S, Saraya A, et al. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res, 2008, 68: 7742–7749.PubMedCrossRefGoogle Scholar
  41. [41]
    Zen Y, Fujii T, Yoshikawa S, et al. Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am J Pathol, 2007, 170: 1750–1762.PubMedCrossRefGoogle Scholar
  42. [42]
    Burkert J, Otto WR, Wright NA. Side populations of gastrointestinal cancers are not enriched in stem cells. J Pathol, 2008, 214: 564–573.PubMedCrossRefGoogle Scholar
  43. [43]
    Hu C, Li H, Li J, et al. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis, 2008, 29: 2289–2297.PubMedCrossRefGoogle Scholar
  44. [44]
    Kelly P N, Dakic A, Adams J M, et al. Tumor growth need not be driven by rare cancer stem cells. Science, 2007, 317: 337.PubMedCrossRefGoogle Scholar
  45. [45]
    Quintana E, Shackleton M, Sabel M S, et al. Efficient tumor formation by single human melanoma cells. Nature, 2008, 456: 593–598.PubMedCrossRefGoogle Scholar
  46. [46]
    Singh S K, Hawkins C, Clarke I D, et al. Identification of human brain tumor initiating cells. Nature, 2004, 432: 396–401.PubMedCrossRefGoogle Scholar
  47. [47]
    Collins A T, Berry P A, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res, 2005, 65: 10946–10951.PubMedCrossRefGoogle Scholar
  48. [48]
    Gu G, Yuan J, Wills M, et al. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res, 2007, 67: 4807–4815.PubMedCrossRefGoogle Scholar
  49. [49]
    Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ, 2008, 15: 504–514.PubMedCrossRefGoogle Scholar
  50. [50]
    O’Brien C A, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature, 2007, 445: 106–110.PubMedCrossRefGoogle Scholar
  51. [51]
    Nowell P C. The clonal evolution of tumor cell populations. Science, 1976, 194: 23–28.PubMedCrossRefGoogle Scholar
  52. [52]
    Shackleton M, Quintana E, Fearon E R, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell, 2009, 138: 822–829.PubMedCrossRefGoogle Scholar
  53. [53]
    Visvader J E, Lindeman G J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer, 2008, 8: 755–768.PubMedCrossRefGoogle Scholar
  54. [54]
    Pece S, Tosoni D, Confalonieri S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell, 2010, 140: 62–73.PubMedCrossRefGoogle Scholar
  55. [55]
    Zhang S, Balch C, Chan M W, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res, 2008, 68: 4311–4320.PubMedCrossRefGoogle Scholar
  56. [56]
    Takaishi S, Okumura T, Tu S, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells, 2009, 27: 1006–1020.PubMedCrossRefGoogle Scholar
  57. [57]
    Boiko A D, Razorenova O V, van de Rijn M, et al. Human melanomainitiating cells express neural crest nerve growth factor receptor CD271. Nature, 2010, 466: 133–137.PubMedCrossRefGoogle Scholar
  58. [58]
    Ma S, Lee TK, Zheng BJ, et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene, 2008, 27: 1749–1758.PubMedCrossRefGoogle Scholar
  59. [59]
    Amin R, Mishra L. Liver stem cells and TGF-beta in hepatic carcinogenesis. Gastrointest Cancer Res, 2008, 2: S27–S30.PubMedGoogle Scholar
  60. [60]
    Tang Y, Kitisin K, Jogunoori W, et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA, 2008, 105: 2445–2450.PubMedCrossRefGoogle Scholar
  61. [61]
    Rountree C B, Senadheera S, Mato J M, et al. Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice. Hepatology, 2008, 47: 1288–1297.PubMedCrossRefGoogle Scholar
  62. [62]
    Ding W, Mouzaki M, You H, et al. CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology, 2009, 49: 1277–1286.PubMedCrossRefGoogle Scholar
  63. [63]
    Lau C K, Yang Z F, Ho D W, et al. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res, 2009, 15: 3462–3271.PubMedCrossRefGoogle Scholar

Copyright information

© Zhejiang University Press, Hangzhou and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Gangming Zou
    • 1
    • 2
  • Jinjun Li
    • 1
  • Jianren Gu
    • 1
  1. 1.State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute, Renji HospitalShanghai Jiaotong University School of MedicineShanghaiChina
  2. 2.Shanghai Key Laboratory for Pediatrics Gastroenterology and Nutrition, Shanghai Institute for Pediatrics Research, Xinhua HospitalShanghai Jiaotong University School of MedicineShanghaiChina

Personalised recommendations